London
· Delayed Price · Currency is GBP · Price in GBX GENinCode Company Description
GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient’s health based on their genes in the United Kingdom and internationally.
Its predictive technology offers patients and physicians with preventative care and treatment strategies.
The company’s invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.
Its tests include Cardio inCode, a genetic test to help user to adopt cardiovascular prevention assesment; Lipid inCode, a genetic diagnostic test for familial hypercholesterolemia FH; SUDD inCode, genetic diagnostic test for familial heart diseases; Thrombo inCode, a genetic test for diagnosis of hereditary thrombophilia and the risk of thrombosis.
In addition, the company offers Thrombo inCode Reproductive Health, is a genetic test that evaluates the impact of hereditary thrombophilia in patients with repeated miscarriages; and ROCA Test, a blood test that determines the risk of a woman having ovarian cancer.
Further, it engages in the medical and scientific research activities. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.
| Country | United Kingdom |
| Founded | 2018 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Matthew Walls |
Contact Details
Address: One St. Peters Square Manchester, M2 3DE United Kingdom | |
| Website | genincode.com |
Stock Details
| Ticker Symbol | GENI |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BL97B504 |
| SIC Code | 8000 |
Key Executives
| Name | Position |
|---|---|
| Matthew Walls | Chief Executive Officer |
| Paul Andrew Foulger | Chief Financial Officer |
| Jordi Puig Gilberte | Chief Operating Officer |